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Abstract  28 
There is increasing awareness of the role genetic risk variants have in mediating vulnerability to psychiatric 29 
disorders such as schizophrenia and autism. Many of these risk variants encode synaptic proteins, influencing 30 
biological pathways of the postsynaptic density and, ultimately, synaptic plasticity. Fragile X Mental Retardation 1 31 
(FMR1) and Cytoplasmic FMRP-Interacting Protein (CYFIP1) contain two such examples of highly penetrant risk 32 
variants and encode synaptic proteins with shared functional significance. In this Review, we will discuss the 33 
biological actions of FMRP and CYFIP1, including their regulation of i) protein synthesis and specifically FMRP 34 
targets, ii) dendritic and spine morphology and iii) forms of synaptic plasticity such as long-term depression. We 35 
draw upon a range of preclinical studies that have used genetic dosage models of FMR1 and CYFIP1 to determine 36 
their biological function. In parallel, we discuss how clinical studies of Fragile X Syndrome or 15q11.2 deletion 37 
patients have informed our understanding of FMRP and CYFIP1 proteins, and highlight the latest psychiatric 38 
genomic findings that continue to implicate FMRP and CYFIP1. Lastly, we assess the current limitations in our 39 
understanding of FMRP and CYFIP1 biology and how they must be addressed before mechanism-led therapeutic 40 
strategies can be developed for psychiatric disorders.     41 
 42 
1. The synapse and postsynaptic density proteins 43 
Neurotransmission between presynaptic and postsynaptic terminals is the adaptive communication mechanism 44 
linking neurons and other cell types into neural circuits and networks, which form the basis of synaptic plasticity, 45 
cognition and behaviour (1,2). The majority of excitatory, glutamatergic synapses in the mammalian brain are 46 
located at small dendritic protrusions, or spines (3), and contain a prominent assembly of proteins at the 47 
postsynaptic membrane known as the postsynaptic density (PSD) (4,5). Proteomic profiling of the PSD has 48 
revealed over 1000 different proteins (6–8), many of which converge on the regulation of synaptic plasticity 49 
through biological pathways controlling protein synthesis, receptor trafficking or structural rearrangements (9–50 
11).  51 
2. Synaptic FMRP: regulator of mRNA and local translation 52 
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One such synaptic protein is Fragile-X Mental Retardation Protein (FMRP), encoded by the FMR1 gene 53 
(Xq27.3)(12) and the monogenic cause of neurodevelopmental disorder Fragile X Syndrome (FXS) (13). FMR1 54 
mRNA is expressed in the neuronal cell body, developing and mature axons, dendrites and dendritic spines, as 55 
well as the nucleus (14,15), but not across all neuronal populations (16,17). FMRP is a RNA binding protein (RBP) 56 
with multiple structural motifs for binding RNA (such as KH domain and RGG box) (18), capable of regulating the 57 
dendritic sequestering, and localisation, of hundreds of target neuronal mRNAs (19,20), either through direct 58 
interactions or via intermediary interactions with noncoding RNA (21,22).  59 
FMRP, its target mRNA and other protein partners, together form large messenger ribonucleoparticles (mRNPs) 60 
(23). Within the mRNP, FMRP plays a key role in the translational silencing of its target mRNA (24–27), required 61 
during the  transport of mRNA along dendrites (28), before synaptic activation results in the docking of the 62 
mRNPs to the spines and subsequent translation (29,30). FMRP specifically regulates the rate-limiting step of cap-63 
dependent mRNA translation initiation by binding to the initiation factor eIF4E and FMRP-binding partner CYFIP1 64 
(see Section 4 later) (31,32), although initiation may also be regulated via FMRP ubiquitination or sumoylation 65 
(33–35). FMRP also controls elongation stages of mRNA translation by stalling ribosomes on FMRP target 66 
transcripts (19,24), although how FMRP switches between the regulation of initiation and elongation is currently 67 
unknown (36). FMRP is therefore a critical mediator of local translation of mRNA targets, acting at both 68 
presynaptic and postsynaptic terminals (24,37,38). Some of the key biological roles of FMRP at postsynaptic 69 
terminals are highlighted in Figure 1.  70 
Beyond translational silencing, FMRP plays other biological roles (39) including RNA editing (40), the regulation of 71 
mRNA target stability (41), and ion-channel binding (42,43), collectively influencing calcium signalling  (44), 72 
activity-dependent neurodevelopment  (45) and the balance of excitatory/inhibitory circuits (46,47). The 73 
additional functions of FMRP might explain instances where FMRP does not appear to be a straightforward 74 
repressor of protein synthesis (48), perhaps most pertinently through FMRP’s ability to influence the stability of a 75 
subset of mRNAs (22,49).     76 
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3. FMRP targets 77 
Considerable effort has been made to identify the mRNAs targeted by FMRP so that biological pathways affected 78 
by mutations in FMR1 can be better predicted. Such studies have used immunoprecipitation followed by either 79 
microarray (50,51) or high-throughput sequencing (19,52) to determine FMRP-bound mRNAs. Due to varied 80 
methodology and tissues (as well as influence from type I and II errors), these lists of FMRP targets differ 81 
considerably (52,53). Therefore, precisely which mRNAs are bound by FMRP is uncertain and likely to be 82 
somewhat tissue-specific. Two studies using mouse cortical tissue and comparable methodology (high-throughput 83 
sequencing of RNA isolated by crosslinking immunoprecipitation) yielded highly overlapping results: 89% of 84 
mRNAs identified as FMRP targets by Darnell and colleagues (19) were also identified by Maurin et al (52). Still, 85 
only a small subset of the proposed targets have been validated (23,49,54–57). 86 
Gene ontology analyses of brain-derived FMRP targets confirm an overrepresentation of genes involved in 87 
functions related to synaptic activity, plasticity, development and anatomy (19,52,58), consistent with studies of 88 
FMRP function. The proteins they encode include both presynaptic and postsynaptic components. Of these are 89 
subunits and interactors of receptor complexes considered central to synaptic plasticity phenotypes associated 90 
with FXS, chiefly the mGluR5 and NMDA receptor signalling complexes (19). The observation that FMRP binds 91 
some presynaptic proteins supports evidence that FMRP regulates protein synthesis during axon development 92 
and synapse formation (59–62).  93 
Whilst studies of FMRP targets have identified probable interactions between FMRP and ribosomal mRNAs, 94 
further work is needed to determine whether the translation of these mRNAs are indeed repressed by FMRP 95 
within the regulatory complex together with CYFIP1 and eIF4E proteins in the cell (31,32).  96 
4. Synaptic CYFIP1: a negative regulator of protein synthesis and cytoskeletal dynamics 97 
Cytoplasmic FMRP-Interacting Protein (CYFIP1) is a highly dynamic synaptic protein involved in numerous 98 
biological pathways through an array of protein-protein interactions (Figure 1) (63). Originally known as a 99 
Specifically Rac1 Activated protein 1 (SRA-1)(64), CYFIP1 was later found to bind with FMRP (12,65), forming a 100 
critical CYFIP1-FMRP complex at the synapse (31). Specifically, FMRP-bound CYFIP1 acts as a non-canonical eIF4E-101 
binding protein (4E-BP) (31), thereby providing competition for the binding of eIF4E to the translation initiation 102 
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complex (eIF4E-eIF4G) (66,67). Overall, it is this eIF4E-CYFIP1-FMRP complex, together with its target mRNA, that 103 
represses translation at dendritic and synaptic sites (31). Upon synaptic activation via Tropomyosin receptor 104 
kinase B (TrkB) or group I mGluRs, eIF4E is released from CYFIP1-FMRP, and permits the translation of target 105 
mRNAs (31). A subsequent study has implicated a MAP-kinase-interacting kinase (MNK)-dependent  pathway in 106 
the release of the inhibitory CYFIP1-FMRP complex from target mRNA, via MNK phosphorylation of CYFIP1 107 
protein, in the early phase of LTP, thereby permitting translation (68).  108 
Aside from its role in regulating protein synthesis, CYFIP1 forms part of the ~400kDa heteropentameric WAVE 109 
regulatory complex, which also contains WAVE1/2/3, ABI1/2, NCKAP1 and HPSC300 components (69). Without 110 
CYFIP1, the WAVE complex promotes actin cytoskeleton remodelling via the Arp2/3 complex (70–72), impacting 111 
on aspects of dendritic spine formation, stability, morphology, migration and excitability (73). The role of CYFIP1 112 
is to maintain the WAVE complex in an inhibited state, until the GTPase, Rac1, causes the dissociation of CYFIP1 113 
from the WRC and allows actin remodelling to proceed via Arp2/3 (74).  114 
CYFIP1 belongs to the two aforementioned complexes, FMRP and WAVE, in a mutually exclusive manner, skewed 115 
towards greater association with the WAVE complex, under basal conditions (74). Notably, synaptic activation 116 
changes the protein conformation of CYFIP1, from globular to planar, and drives the distribution of CYFIP1 protein 117 
further  towards the RAC1-WAVE complex, with a concomitant decrease in the eIF4E-CYFIP1 complex (71,74,75). 118 
Therefore, CYFIP1 is a central molecular mediator that bridges the two processes of mRNA translation and actin 119 
dynamics, both essential for synaptic plasticity (76–78). Other molecular roles for CYFIP1 are being explored, 120 
including its role presynaptically. For instance, presynaptic function is altered in the hippocampus of juvenile 121 
Cyfip1 KO mice, thought to derive from changes in presynaptic terminal size and enhanced vesicle release 122 
probability, and driven by dysregulation of the WAVE complex (79). These findings closely align with previous 123 
findings in cyfip1 mutant fly models that specifically found alterations in actin polymerisation in presynaptic 124 
terminals. (65,80). More recently, Cyfip1 KO mice were found to have decreased myelination of callosal axons, 125 
alongside impaired presynaptic neurotransmission in the corpus callosum (81). 126 
CYFIP1 has a closely related paralogue, CYFIP2, with over 88% amino acid identity (12). Like CYFIP1, CYFIP2 is 127 
found at excitatory (82) and inhibitory (83) synapses, and binds both to the WAVE complex (63,69) and to FMRP 128 
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(12). Interestingly, CYFIP2 additionally binds to FMRP-related proteins, FXR1P and FXR2P, while CYFIP2 mRNA is a 129 
target of FMRP (19), implying a further layer of feedback between FMRP and the family of CYFIP proteins. 130 
However, the molecular redundancy between these paralogues is limited, given that the deletion of both copies 131 
of CYFIP1 is embryonically lethal (74,84). Furthermore, CYFIP1, but not CYFIP2, has been consistently associated 132 
with neuropsychiatric disorders (82,83), although see (85).  133 
5. Psychiatric disorders and the synapse 134 
Considerable  evidence suggests that a wide range of neuropsychiatric disorders such as FXS, Autism Spectrum 135 
Disorders (ASDs), schizophrenia, intellectual disabilities (ID), and bipolar disorder exhibit convergent synaptic 136 
pathology (6,32,86–91). Synaptic dysfunction has been observed at several levels including: genetic alterations 137 
(92–94); aberrant proteins (95) and their translation (25,96–98); molecular signalling pathways (99–101); spine 138 
morphology (102); aberrant synaptic plasticity (103–105); neurocircuitry and connectivity (106). These 139 
interrelated observations highlight impaired synaptic function as a common feature of several neuropsychiatric 140 
disorders (91,94,107).  141 
In light of this view, and the biological importance of FMRP and CYFIP1 at the synapse (outlined in Sections 2 and 142 
4), we will now consider the role of FMRP and CYFIP1 in the aetiology of psychiatric disorders, using data from 143 
human patient studies, especially psychiatric genomics, and preclinical models.       144 
                                                                                                     145 
6. FMRP and FMRP targets in psychiatric disorders  146 
6.1 FXS patients and Fmr1 knockout models 147 
In humans, the transcriptional silencing of the FMR1 gene by a triplet repeat expansion (beyond 200 repeats, 148 
typically ~800) in the 5- untranslated region of FMR1 (108) leads to FXS (13,109). FXS patients display a broad 149 
range of abnormalities including increased immaturity of dendritic spines (110–112); altered molecular signalling 150 
(23); increased levels of basal protein synthesis (113,114); altered neuron and circuit excitability (115); structural 151 
and connectivity defects in brain networks (116); and a range of cognitive and behavioural phenotypes that 152 
overlap considerably with intellectual disability and ASD (117–119). Indeed, FXS represents the single most 153 
common form of inherited ID with a prevalence of 1:4,000 males and 1:8,000 females (120) and the most 154 
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common, single-gene cause of ASD (108,117). FMRP may also be involved in other neuropsychiatric disorders, 155 
beyond FXS and related ASDs, including schizophrenia and bipolar disorder (121–125).  156 
The effects of Fmr1 mutations have been interrogated preclinically for 25 years through the Fmr1 knockout (KO) 157 
mouse model (126), and with the advent of modern gene-targeting technologies, the Fmr1 KO rat model 158 
(127,128). Many of the features of human FXS have been recapitulated in Fmr1 KO mouse and rat models, 159 
especially in three key areas: dendritic spine maturation (112,127,129,130); elevated basal protein synthesis  160 
(127,131–133); and behavioural/cognitive phenotypes, including ASD-like abnormalities (134), abnormalities in 161 
social interaction and interest (135), social anxiety (136) and reduced behavioural flexibility/reversal learning in a 162 
variety of tasks (127,137–141).  163 
In addition to heightened global protein synthesis, Fmr1 KO rodents display a lack of metabotropic glutamate 164 
receptor (mGluR)-dependent translational control, which results in an elevated protein synthesis-dependent form 165 
of synaptic plasticity, known as metabotropic glutamate receptor (mGluR)-mediated long-term depression 166 
(127,142–145). Increased mGluR-dependent translation is thought to occur through excessive activation of the 167 
mGluR5 subtype, given that reductions in mGluR5 expression (132), or the mGluR5 antagonist MPEP (46,146), can 168 
rescue several Fmr1 KO phenotypes. The altered mGluR5 signalling in the absence of Fmr1 appears to be 169 
mediated through the preferential interaction of mGluR5 with activity-dependent isoforms of Homer1 over 170 
constitutive Homer proteins (147,148).  171 
The deletion of Fmr1 results in the loss of the repressive eIF4E-Cyfip1-FMRP complex, which de-represses the 172 
initiation complex, eIF4F, required for cap-dependent translation initiation of FMRP targets (149). It was shown 173 
that an inhibitor of the eIF4F complex, which creates free eIF4E, increases the abundance of the eIF4E-CYFIP1-174 
FMRP complex (with a parallel decrease in the CYFIP1-WAVE complex) in Fmr1 KO mice, and the restoration of 175 
this imbalance rescues spine and memory deficits in these animals (150). Hence, studies of the Fmr1 KO rodent 176 
model have illuminated a variety of molecular mechanisms relevant to FXS, especially those pertinent to the 177 
regulation of protein synthesis, and may provide biological targets for therapeutic intervention (24), 178 
complementing ongoing clinical trials in human FXS patients (151,152).    179 
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6.2 FMRP and FMRP targets in psychiatric genomic studies 180 
Beyond repeat expansions in the FMR1 gene, a number of rare pathogenic point mutations have been reported 181 
that cause developmental delay and intellectual disability reminiscent of FXS (153–157). Further evidence 182 
suggests that mutations in the autosomal homolog FXR2 gene might also contribute to intellectual disability (158–183 
160). Whilst variants affecting the related FXR1 gene confer risk to schizophrenia, bipolar disorder and autism 184 
(161–165), the genetic link between FMR1 and psychiatric disorders derives from enrichment of association 185 
within the gene targets of FMRP (among which the Fragile-X family genes themselves are included).  186 
A set of FMRP target mRNAs derived from a study of mouse cortical polyribosomes (19) have been recurrently 187 
highlighted in the literature due to their enrichment for genes associated with an array of psychiatric disorders. 188 
Through large-scale genome-wide association studies, these 842 FMRP targets have been shown to be genetically 189 
associated with schizophrenia (161,162), autism (166), major depressive disorder (167) and bipolar disorder (58). 190 
In addition to the risk conferred from common variation, this gene set is enriched for rare variants from patients 191 
with schizophrenia (168–171), autism (172) and bipolar disorder (173), de novo variants from patients with 192 
schizophrenia (174) and autism (175–177), and to a lesser extent copy number variants from patients with 193 
schizophrenia (178–180). The convergence of risk from multiple different types of genetic variant forms a strong 194 
evidence base implicating this gene set in psychiatric pathology. Conversely, FMRP targets derived from a study of 195 
human embryonic kidney cells (51) do not appear to be associated with psychiatric disorders (166,168), 196 
highlighting the tissue specificity of these relationships.  197 
Brain FMRP targets overlap considerably with other gene sets associated with psychiatric disorders, such as genes 198 
encoding postsynaptic density proteins and those involved in calcium signalling, synaptic plasticity, learning and 199 
memory (19,52,58,181). However, despite these overlaps, the enrichment of brain FMRP targets for association 200 
with psychiatric disorders is independent (58,162,168) and proportional to the confidence of binding by FMRP 201 
(58). Moreover, in many instances, it appears that FMRP targets capture subsets of these other gene sets in which 202 
genetic association is concentrated (58). Hence, this set of genes locally regulated by FMRP during plasticity and 203 
development at the synapse may represent a collection of biological pathways important for the manifestation of 204 
a range of psychiatric disorders. 205 
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7. CYFIP1 in psychiatric disorders 206 
7.1 15q11.2 copy number variants and Cyfip1 dosage models 207 
The proximal long arm of human chromosome 15 (15q11.2-13.3) is a region of numerous low copy repeats that 208 
can lead to aberrant meiotic chromosomal rearrangements. These result in deletions or duplications of sections 209 
of DNA, known as copy number variants (CNVs), and occur at any of five common breakpoints (BP1-BP5) on 210 
chromosome 15 (182). Neurodevelopmental psychiatric disorders Prader-Willi syndrome (PWS) and Angelman 211 
syndrome (AS) are caused by deletions of paternal or maternal origin, respectively, and occur as either large 212 
deletions (type I, between BP1-BP3) or smaller deletions (type II, between BP2-BP3). Meanwhile, CYFIP1 is 213 
cytogenetically positioned in the non-imprinted 500kb region between BP1 and BP2 on chromosome 15 (15q11.2 214 
interval), along with 3 additional genes: nonimprinted in Prader/Willi Angelman 1 (NIPA1) and 2 (NIPA2), and 215 
tubulin gamma complex associated protein (TUBGCP5) (183). The 15q11.2 chromosomal region was first 216 
implicated with neurodevelopmental psychiatric disorders through the observation that type I deleted PWS or AS 217 
patients, who lack the 15q11.2 interval, had more severe behavioural phenotypes compared to type II deleted 218 
patients, in which the 15q11.2 interval is intact (184,185). Later, patients were identified with deletions and 219 
duplications between BP1 and BP2, which specifically flanked the 15q11.2 interval itself (182). 220 
Deletions or duplications of 15q11.2 are present in 1 out of 100 people that present for genetic screening, whilst 221 
incidence in the general population is likely to be nearer 1 in 500 people (186). The CNV causes patients to display 222 
language/motor deficits or delays, behavioural problems, autism and seizures (187–189), with deletions the most 223 
impactful on cognition (187) and referred to as Burnside-Butler syndrome (182,186). It was recently observed that 224 
15q11.2 deletion patients have structural and functional changes in the brain that likely relate to the 225 
accompanying cognitive phenotypes, including a smaller left fusiform gyrus and altered activation in the left 226 
fusiform and the left angular gyri using fMRI (190). In subsequent diffusion tensor imaging (DTI) studies, 15q11.2 227 
deletion carriers show increased fractional anisotropy (191), indicating alterations in the white matter 228 
microstructure (192) . In keeping with these findings, white matter changes in 15q11.2 deletion patients closely 229 
mirror the phenotypes of FXS patients (193), suggesting a common pathogenic pathway derived from disruption 230 
of CYFIP1-FMRP protein complexes. Although the 15q11.2 deletion is not fully penetrant, as  a significant 231 
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proportion of the general population are healthy carriers with no overt phenotypes (194), it is likely that 232 
subclinical cognitive phenotypes exist even in these ‘healthy’ carriers (195).     233 
Among the genes located within the 15q11.2 locus, CYFIP1 is widely regarded as the most likely to confer the 234 
biological and behavioural phenotypes associated with 15q11.2 BP1-BP2 CNVs (84,191). This is due, in part, to its 235 
known functional association with the FXS-relevant protein FMRP (see Sections 2, 3, 4 & 6) (31,74). Furthermore, 236 
the expression of CYFIP1 and components of the WAVE complex is disrupted in patients carrying 15q11.2 237 
deletions (196); iPSCs derived from these patients exhibit cellular phenotypes mediated by the CYFIP1-WAVE 238 
complex (197); and the knockdown of CYFIP1, specifically, in human progenitor cells alters cytoskeletal 239 
remodelling (198). However, the biological roles of the three remaining genes within the 15q11.2 interval requires 240 
further delineation, as, like CYFIP1, they are all CNS expressed and their expression is altered in patients with 241 
15q11.2 CNVs (199).  242 
Great strides have been made in understanding the consequences of altered Cyfip1 dosage through a variety of in 243 
vitro and in vivo rodent preclinical models. For instance, the heterozygous deletion of Cyfip1 in mice results in 244 
changes in dendritic and spine morphology (74,82), which are similarly observed in a forebrain-specific 245 
conditional homozygous knockout model (83), whilst the over-expression of Cyfip1 also impinges on dendrite and 246 
spine morphology (82,200). Meanwhile, Cyfip1 appears to affect protein synthesis under basal and activity-247 
dependent conditions. The knockdown of Cyfip1 in cortical neurons in vitro increases the translation of FMRP 248 
target Arc under basal conditions and also ablates the activity-dependent translation of Arc, using BDNF 249 
treatment to mimic synaptic activation (74). Similar findings were reported in vivo using Cyfip1 heterozygous KO 250 
mice, whereby BDNF treatment was insufficient to release the Cyfip1-FMRP complex from eIF4E, preventing the 251 
formation of the eIF4F complex, which subsequently prevented activity-dependent translation of Arc protein (68).  252 
Measures of synaptic plasticity in preclinical models of altered Cyfip1 dosage have revealed elevated levels of 253 
mGluR-mediated long-term depression, which become disassociated from mRNA translation pathways (84) – 254 
findings that are reminiscent of Fmr1 KO rodent models (127,144). Over-expressing Cyfip1 in CA1 hippocampal 255 
neurons can lead to increased excitatory neurotransmission, and a concomitant decrease in GABAergic 256 
neurotransmission at inhibitory synapses, shifting the overall excitation/inhibition balance towards excessive 257 
11 
 
excitation (83). The same study also showed that the conditional, homozygous knockout of Cyfip1 in CA1 258 
hippocampal neurons increased inhibitory GABAergic neurotransmission, along with increased expression of 259 
GABA receptors, suggesting a shift of excitation/inhibition balance towards greater inhibition (83). However, in 260 
the haploinsufficient Cyfip1 mouse model, which better models the reduced dosage of CYFIP1 in 15q11.2 deletion 261 
patients, GABAergic signalling remains unaltered in the hippocampal dentate gyrus (201).   262 
Brain connectivity and white matter architecture appear to be especially sensitive to reduced Cyfip1 dosage. In 263 
Cyfip1 heterozygous KO mice, bilateral connectivity was shown to be reduced across multiple brain regions using 264 
resting-state functional magnetic resonance imaging (81). These alterations were likely due to changes in corpus 265 
callosal white matter architecture, measured by i) a decrease in fractional anisotropy using DTI and ii) altered 266 
levels of myelination and presynaptic function. Furthermore, many of the white matter phenotypes, including 267 
decreased fractional anisotropy, were mirrored in a comparable rat model of Cyfip1 haploinsufficiency (202). 268 
However, it is currently unclear why fractional anisotropy might be decreased in rodent models of reduced Cyfip1 269 
dosage, but increased in 15q11.2 deletion patients. This will require further study and may alter our current 270 
perception of the effect of CNVs of the 15q11.2 interval.    271 
In vivo models of altered Cyfip1 dosage also offer the chance to thoroughly assess changes in behaviour and 272 
cognition; prominent features in 15q11.2 deletion (and duplication) patients. Bozdagi and colleagues were the 273 
first to behaviourally assess Cyfip1 haploinsufficient mice, and found many aspects of spatial and fear learning 274 
and memory to be intact, with the exception of a rapid loss of extinction memory assessed using the inhibitory 275 
avoidance paradigm (84). Subsequent analysis of Cyfip1 heterozygous KO mice and rats have shown specific 276 
deficits in motor learning (81,203), sensorimotor gating measured by prepulse inhibition (81) and behavioural 277 
flexibility (202). Meanwhile, the over-expression of Cyfip1 results in cellular phenotypes, particularly at the 278 
dendritic level (200), but appears to have little effect on behaviour and cognition, with the exception of  279 
exaggerated fear responses (204). Overall, there is accumulating evidence that altering the dosage of Cyfip1 in 280 
preclinical models leads to profound alterations in cellular and plasticity phenotypes, alongside mild behavioural 281 
phenotypes, many of which overlap with FXS and the Fmr1 KO model (Figure 2), but also closely match the key 282 
clinical phenotypes of patients with chromosomal deletions (and duplications) of the CYFIP1-containing 15q11.2 283 
interval.      284 
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7.2 CYFIP1 variants in psychiatric genomic studies 285 
Genomics studies in psychiatric populations have implicated the 15q11.2 BP1-BP2 deletion with a wide range of 286 
psychiatric, neurodevelopmental disorders, including a 2- to 4-fold increased risk for schizophrenia (205,206); a 287 
finding that has been replicated in many subsequent studies (92,179,207–210). Additionally, 15q11.2 deletions, 288 
and duplications, predispose individuals to a five-fold risk of epilepsy (211), developmental and intellectual 289 
disability (212–214), ADHD (215), major depression (216) and autism (187,217) (for further review, see (182,186)). 290 
Meanwhile,  common variants in CYFIP1 have been reported to increase risk for ASD (218,219). Consistent with 291 
the genetic findings, proteomic analysis of prefrontal cortex post-mortem tissue from schizophrenia patients 292 
revealed altered levels of CYFIP1 and other proteins belonging to protein synthesis pathways (220).  293 
The relevance of CYFIP1 to schizophrenia becomes especially apparent when considered in the wider context of 294 
its biological actions within protein complexes. CYFIP1 is involved in the regulation of ARC protein and ARC-295 
related genes, sometimes referred to as the ‘ARC complex’ (a gene ontology-based complex). CYFIP1 was first 296 
associated with schizophrenia in studies that showed an enrichment of the ARC complex (containing 25 genes, of 297 
which CYFIP1 is one) in de novo CNV deletions from patients with schizophrenia (92). The genetic association of 298 
this ARC complex with schizophrenia has subsequently been confirmed by exome sequencing studies that 299 
assessed SNVs and indels (168,174) and larger studies of CNV deletions (178,179). Furthermore, the genetic 300 
association with schizophrenia of FMRP targets (Section 6.2), which are regulated by the CYFIP1-FMRP complex, 301 
lends additional evidence to the relevance of CYFIP1 to schizophrenia.   302 
8. Summary of findings and future directions 303 
FMRP and CYFIP1 are hubs for several biological pathways critical to synaptic plasticity. From preclinical models, 304 
we know that reduced expression of either CYFIP1 or FMRP results in a set of core phenotypes: altered spine and 305 
dendritic morphology, dysregulated protein synthesis and elevated long-term depression. A further layer of 306 
complexity is added when it is considered that the concerted action of FMRP and CYFIP1, as part of the CYFIP-307 
FMRP complex, represses the translation of hundreds of FMRP targets, likely influencing multiple downstream 308 
pathways. The importance of this system to synaptic function is recurrently highlighted by genetic studies 309 
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demonstrating the risk conferred to psychiatric disorders by variants affecting genes encoding CYFIP1, FMRP and 310 
their targets.  311 
Nevertheless, there are many questions that still surround the biology of FMRP, CYFIP1 and FMRP targets in 312 
health and disease. For example, whilst FMRP synaptic biology is well-characterised and preclinical techniques 313 
can reverse disorder-relevant phenotypes (132,151), attempts to move these therapies into the clinic have been 314 
largely ineffective (152). This suggests that further mechanistic insights into the actions of FMRP are needed, 315 
alongside further refinement of therapeutic targets and/or strategies. Similarly, whilst FMRP targets are a 316 
disease-relevant group of mRNAs, their precise identity and biological function remains under-explored. 317 
Meanwhile, the study of CYFIP1 has seen unprecedented advances in recent years, revealing an extensive array of 318 
synaptic roles, far beyond its initial characterisation as a binding partner to FMRP. Despite the rapid expansion of 319 
CYFIP1 studies, many fundamental questions remain and can be addressed in future studies, aided by advances in 320 
RNA sequencing, genetic-editing and proteomic technologies. Whilst extensively characterised, it is also worth 321 
noting that the behavioural phenotypes in models of Fmr1 and Cyfip1 deletion are only broadly similar, and in 322 
some cases diametrically opposed (221). These behavioural discrepancies could reflect the diversity of biological 323 
function, but might also derive from highly transient and localised interactions between these two proteins.        324 
Penetrant risk variants affecting this biological pathway increase psychiatric vulnerability to a range of psychiatric 325 
disorders. For example, CNVs affecting CYFIP1 predispose carriers to increased risk for schizophrenia (mainly 326 
15q11.2 deletions), autism and intellectual disability (mainly 15q11.2 duplications), and likewise FMR1 deletions 327 
predispose carriers to autism and intellectual disability. These apparently pleiotropic effects might suggest that 328 
the categorical nature of diagnoses for psychiatric disorders needs to be fundamentally re-evaluated. Indeed, at 329 
the clinic, there are many common patient symptoms that span across diagnostic categories, and patients often 330 
present with comorbidities. The genomic findings point towards a continuum of causality, whereby common 331 
biological mechanisms, influenced by a range of convergent genetic factors, span across the traditional diagnostic 332 
boundaries of psychiatric disorders. The highly tractable mechanism of CYFIP1-FMRP and the regulation of ARC, is 333 
one such biological pathway, offering a unique entry point for continued study and phenotypic rescue. The future 334 
development of novel, mechanism-based therapeutic approaches will be vital to meet the ever-growing need to 335 
treat these common, yet debilitating, psychiatric disorders.    336 
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Figure Legends 903 
Figure 1:  The biological roles of synaptic FMRP and CYFIP1 proteins in postsynaptic neurons. FMRP plays a key 904 
role in negatively regulating the translation of hundreds of FMRP targets, including ARC, by forming a complex 905 
with CYFIP1, alongside initiation factor, eIF4e. The control of mRNA translation, and its repression by the CYFIP1-906 
FMRP complex, is partly mediated through activation of upstream NMDA and mGluR5 receptors. FMRP targets 907 
such as ARC can drive changes in synaptic plasticity through regulation of AMPA receptors 908 
trafficking/internalisation and increasing actin cytoskeleton stability. Meanwhile, CYFIP1 can bind and inhibit the 909 
38 
 
WAVE regulatory complex, thereby blocking the promotion of actin cytoskeleton rearrangements. Preclinical 910 
evidence suggests that under conditions of synaptic activation, CYFIP1 redistributes between the two main 911 
complexes, with greater association with the WAVE complex and a reciprocal decrease with the FMRP complex. 912 
Figure 2:  Core set of overlapping phenotypes from preclinical Fmr1 and Cyfip1 deletion models. Rodent models 913 
of Fmr1 deletion (Fmr1-/y, whereby the single X-linked copy of Fmr1 is deleted in males) or heterozygous Cyfip1 914 
deletion (Cyfip1+/-) mirror clinical populations with Fragile X Syndrome and 15q11.2 CNV deletions, respectively. 915 
Moreover, these two rodent models share a core set of functionally-related neurobiological phenotypes, 916 
including i) altered spine and dendritic morphology, ii) dysregulated protein translation and iii) elevated long-term 917 
depression. Further work is required to fully delineate the consequences of Fmr1 and Cyfip1 deletion, as well as 918 
characterise the similarities. 919 
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